McDermott Will & Emery and Marcum LLP are committed to sharing the best information available concerning the Coronavirus (COVID-19) pandemic to our clients and colleagues during this time. The evolving ecosystem in the life science and biotechnology sector creates new challenges for companies throughout all stages of their lifecycle. With those new challenges come new opportunities.
Please tune in for this installment of Marcum’s informative webinar series ‘Marcum New England Life Science and Biotech Summit,’ where community experts will share valuable information and insights on how to navigate the landscape and seize opportunities to position yourself for success. Many life sciences companies are working faster than ever to discover new treatments and a vaccine for COVID-19. This race to innovation has increased collaborations between competitors in the industry and raised questions on the intellectual property (IP) challenges going forward for life sciences innovators to protect and enforce their IP rights.
This joint session will feature a panel of subject matter experts as they discuss how to manage IP issues in these uncertain times from a legal, damages and industry perspective.
- Challenges of Collaboration
- Challenges of Patent Enforcement
- Opportunities with Government Funding, Investments and IPOs
Sarah Chapin Columbia – Partner | McDermott Will & Emery
Bill Scally, CFE – National Litigation Support Services Leader | Marcum LLP
Steve Bossone – Chief Patent Counsel | Alnylam Pharmaceuticals